BACKGROUND: The use of flow-diversion to treat ophthalmic segment aneurysms (OSA) has not been well evaluated. OBJECTIVE: To assess the visual outcomes, the obliteration rate, and the need for retreatment of OSA treated by the pipeline embolization device (PED). METHODS: Patients who underwent treatment with PED for OSA from 2009 to 2014 were selected and retrospectively reviewed. Patient's age, sex, mode of presentation, and aneurysm size were recorded. The complication rates, the need for retreatment (due to recurrence of the aneurysm or worsening symptoms), the aneurysm occlusion rates, the evolution of visual symptoms, and the evolution of headache/retro-orbital pain were registered. RESULTS: Forty-one patients harboring 44 OSA treated by flow-diversion were identified. Females constituted 87.80% (37/41) of the cohort. The mean age was 59.16 ± 12.54 years. At final angiographic follow-up, 77.27% (34/44) had complete occlusion, 6.81% (3/44) had near-complete occlusion, and 15.90% (7/44) had incomplete occlusion. Of the 22 symptomatic OSA, complete resolution or significant improvement was noted in 72.72% (16/22), while worsening of symptoms occurred in 4.54% (1/22). Five patients out of 22 (22.72%; 5/22) had no significant changes in their symptoms. The complication rate was 2.27% (1/44). The mortality rate was 0%. CONCLUSION: The low complication rate, the high obliteration rate, and the high rate of improvement in the visual symptoms make flow-diversion an appealing option for the treatment of OSA.
BACKGROUND: The use of flow-diversion to treat ophthalmic segment aneurysms (OSA) has not been well evaluated. OBJECTIVE: To assess the visual outcomes, the obliteration rate, and the need for retreatment of OSA treated by the pipeline embolization device (PED). METHODS:Patients who underwent treatment with PED for OSA from 2009 to 2014 were selected and retrospectively reviewed. Patient's age, sex, mode of presentation, and aneurysm size were recorded. The complication rates, the need for retreatment (due to recurrence of the aneurysm or worsening symptoms), the aneurysm occlusion rates, the evolution of visual symptoms, and the evolution of headache/retro-orbital pain were registered. RESULTS: Forty-one patients harboring 44 OSA treated by flow-diversion were identified. Females constituted 87.80% (37/41) of the cohort. The mean age was 59.16 ± 12.54 years. At final angiographic follow-up, 77.27% (34/44) had complete occlusion, 6.81% (3/44) had near-complete occlusion, and 15.90% (7/44) had incomplete occlusion. Of the 22 symptomatic OSA, complete resolution or significant improvement was noted in 72.72% (16/22), while worsening of symptoms occurred in 4.54% (1/22). Five patients out of 22 (22.72%; 5/22) had no significant changes in their symptoms. The complication rate was 2.27% (1/44). The mortality rate was 0%. CONCLUSION: The low complication rate, the high obliteration rate, and the high rate of improvement in the visual symptoms make flow-diversion an appealing option for the treatment of OSA.
Authors: F Di Maria; S Pistocchi; F Clarençon; B Bartolini; R Blanc; A Biondi; H Redjem; J Chiras; N Sourour; M Piotin Journal: AJNR Am J Neuroradiol Date: 2015-08-13 Impact factor: 3.825
Authors: Apar S Patel; Christoph J Griessenauer; Christopher S Ogilvy; Ajith J Thomas Journal: Interv Neuroradiol Date: 2016-02-22 Impact factor: 1.610
Authors: M S Park; C Kilburg; P Taussky; F C Albuquerque; D F Kallmes; E I Levy; P Jabbour; I Szikora; E Boccardi; R A Hanel; A Bonafé; C G McDougall Journal: AJNR Am J Neuroradiol Date: 2016-01-14 Impact factor: 3.825
Authors: Pervinder Bhogal; Victoria Hellstern; Hansjörg Bäzner; Oliver Ganslandt; Hans Henkes; Marta Aguilar Pérez Journal: Front Neurol Date: 2017-08-07 Impact factor: 4.003
Authors: Mario Zanaty; Nohra Chalouhi; Robert M Starke; Pascal Jabbour; Katherine O Ryken; Ketan R Bulsara; David Hasan Journal: Case Rep Vasc Med Date: 2016-03-16